- Home
- URGN vs ADV Comparison
URGN vs ADV Comparison
Compare URGN & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- ADV
- Stock Information
- Founded
- URGN 2004
- ADV 1987
- Country
- URGN United States
- ADV United States
- Employees
- URGN N/A
- ADV N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- ADV Business Services
- Sector
- URGN Health Care
- ADV Consumer Discretionary
- Exchange
- URGN Nasdaq
- ADV Nasdaq
- Market Cap
- URGN 463.2M
- ADV 420.4M
- IPO Year
- URGN 2017
- ADV N/A
- Fundamental
- Price
- URGN $10.38
- ADV $1.47
- Analyst Decision
- URGN Strong Buy
- ADV Strong Buy
- Analyst Count
- URGN 7
- ADV 1
- Target Price
- URGN $36.75
- ADV $3.50
- AVG Volume (30 Days)
- URGN 635.6K
- ADV 360.6K
- Earning Date
- URGN 05-12-2025
- ADV 05-12-2025
- Dividend Yield
- URGN N/A
- ADV N/A
- EPS Growth
- URGN N/A
- ADV N/A
- EPS
- URGN N/A
- ADV N/A
- Revenue
- URGN $90,398,000.00
- ADV $3,566,324,000.00
- Revenue This Year
- URGN $36.82
- ADV N/A
- Revenue Next Year
- URGN $119.10
- ADV N/A
- P/E Ratio
- URGN N/A
- ADV N/A
- Revenue Growth
- URGN 9.29
- ADV N/A
- 52 Week Low
- URGN $8.94
- ADV $1.11
- 52 Week High
- URGN $20.70
- ADV $4.68
- Technical
- Relative Strength Index (RSI)
- URGN 48.46
- ADV 55.91
- Support Level
- URGN $9.63
- ADV $1.27
- Resistance Level
- URGN $11.75
- ADV $1.41
- Average True Range (ATR)
- URGN 0.82
- ADV 0.08
- MACD
- URGN -0.02
- ADV 0.04
- Stochastic Oscillator
- URGN 32.90
- ADV 96.36
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.